Good Thank our Agnes. you afternoon XXXX everyone for you, and call. third joining earnings quarter thank
XX% by our press growth, mass afternoon, release QX, cytometry. As revenue strong detailed had we in powered in this
to tools revenue into last as deeper provide customers immune premier the adopt few quarters, accelerated our function. Over has insights
the instrument strength This world Imaging saw in Hyperion placements robust around quarter, our we with System. exceptional
prestigious publications, evidence in a seminal publication with of are first clinical expansion mass including We our cytometry market seeing couple a of journal.
update today. will progress We on you our
for period. revenue begin Vikram and to taking over for questions. offering closing more third the As Total turn remarks $XX detailed the increase an an strategy. review XX% and our CFO, financial from million, our the markets I'd and I'll with quarter overview ago the for was before of a to year Then like has discuss of our results then been quarter norm, Jog, financial call
in Our both cytometry instruments with decline business. consumables, and a our in mass in but strength results third quarter microfluidic included considerable genomics
placements and instrument acceleration robust cancer were Hyperion centers, Systems. Systems research translational in and This with quarter, Helios Imaging across there
a pipeline quarters, well to notable last a funnel prospects to Mass adoption usage. Immune contributing purchases Panel year Maxpar compared seeing at early other ramping growth larger Human Monitoring of including significant the are cytometry who our as consumable coming were as scaling over adopters, with consumables products, of is from We this time. repeat their
publications We cytometry are with XX% XXX premier have adoption in and year. the instrument beginning of since global mass commensurate the the uptick technologies. our seeing profiling technology an In world, from mass around publications over efforts insights XXXX, research well cytometry grown
we For genomics, work more have do. to microfluidic
of our As content we drive series adoption implementing expand team of the customer a our our high-throughput business, to is genomics newer workflows. strategies base for and
cash take will our business immuno-oncology Closing management. our on strategy the on we of confident as focused long-term general a initiatives of and these remain microfluidics overview, results market part details strategy our More and later. multi-omic immunology. leverage financial disciplined up potential in reflected quarter and While operating expansion also the time, the this
updates call plenty costs of the We and multiyear excellence FOX, ahead, There risks manage to methodical providing we'll future. achieve will With on the we opportunity have to Brad April, Fluidigm the I Board is and phase to be and steps program first and our program. in operating improvement. implementing it execution in are in be continuous progress patient change. our a up program; the on we ramping since drive taken
regions. a quarter, discussion our in our to expectations. All of well our our exceeding Let's geographic revenue did performance regions now this turn
Adding cytometry adoption we countries an with performance important multiple as XX% revenues Asia-Pacific the these Japan, and China quarter Asia-Pacific the in Japan, performance were in again. in institutions. Year-over-year milestone placements more industrial trend a in was reflecting We top traction color in well as by both this medical third the strong mass powered performer, in in China system up hit had to and India. quarter with region.
-- quarter year-over-year further to great third services increasing demand, areas European sales their funding have the in CRO see and Shifting place team again, revenue region. XX%. pharma the consumables team focus seeing to are this we research. sales strong have growth been to investing great driving were addition, We in we Customers both and in a revenues leaders In in our the were environment and quarter. service technologies in up in up, Europe, capitalize on opportunity. a
example, our in deploying an me to University Helios in CyTOF state-of-the-art will be are for technology to research for mass diabetic to cytometry funding and the is flow their future. in cytometry participation that problems, kicked those asthma, their told use forming to We new new added competitiveness research has immunotherapy. such look initiatives Queen's disease world-leading forward facility. to Europe, and in They CyTOF institution health off eye pushing We've consortia programs. in fundamental new invested a improves diseases, clinical insights. ensure Belfast complications building "a and large and global and As boundaries cardiovascular in core sepsis. inflammatory game lung that academic including tackle changer" work both major their the talking to are as more It detail speaking, and powers programs. focus about across COPD, in Broadly researchers and on anticipated this pharma This
us soft has market, years. growth. a two largest This the region been our to delivered XX% the over past for U.S. spot year-over-year Turning
first we established However, we two ago. arrived on the the years time quarter, last since growth that for I'm pleased building I momentum sequential delivering are
Similar we uptake We've Our key hit seeing this Europe, of has placements Hyperion U.S. has Imaging comprehensive improved Imaging customers strong System. Hyperion milestones massively financial centers. with mass for in the technology critical to invest team our performance for region. cytometry. are instrument Systems Particularly, in a cancer
one in sale the Hyperion example, of we an are motivated our There in accreditation application. a like funnel. sold University part this to opportunities Miami, sales their NCI As by additional
we the are seeing As XXXX, the around end all approach we of momentum world.
CROs, on cancer centers. translational of pipeline executing opportunities robust are across a academic, We targeted and research,
large and future, add see we our at opportunities Looking grow. capacity expand customers base needs as towards their to the existing research customer
third last to placements As saw trend, capacity a expansion. of a continuation our cytometry of we instrument quarter's related mass approximately
We have growth. for ample headroom
Now, thus cells, a Fluidigm demand a questions workflows tools leading answer of strategy. increasingly tissues, our that brief multi-omic. and address view overview to are single-cell-level of a researchers analysis. and well-positioned Increasingly, circulating XXX-degree tools that provider require biomarkers, and is as long-term
opportunity pregnancy conditions, infectious to us or insights large chronic areas Our a premier particular, and as huge this disease, these many diseases funding scientific this applications. of believe other to preterm We the research In for mass needs and more capability. labor, flows across of a provide at range powered immuno-oncology by patient inflammatory few. to translational microfluidic a deep and cutting-edge like name autoimmune, technologies for intersection is move a diseases. market will tools, of areas Clearly, cytometry just those
grow to resulting executing market accounts, instrument technologies delivering double-digit via comprehensive services. Combining strategic build We in opportunities, streams recurring to innovation revenue long-term multi-omic revenue partnerships and are streams, enhanced workflows large at with placements and strategy recurring growth. end-to-end our add is essential excited or influential new our
in customers hosted role early and September, context tissue health group microenvironment discussions well to the market Crohn's critical These than the to was who powered cytometry by our Group user accelerating delivering of data-driven and coupled Moving lymphoma, focused Global their delivery, the more In Annual moved drug we our resistance. to showcasing we with imaging insights, and Two are have presentations capabilities were as heterogeneity response, disease, Imaging and Mass from cancer mass our meeting now cytometry important Global encephalitis, oriented adoption. Meetings, year, Meeting. XX in Cytometry that our attendees had to We User disease adopters studies, imaging characterize for group execution first tumor of on a throughout regionally unimaginable. made lung user User Group the at pharma through year on tumor used second business and greater mass this as meetings. insights programs once technologies exploring XXX with advances quarter, Annual
an experience new were Visiopharm Phenomap customers user and solution announced able from with Visiopharm. the exciting we software to group First, automated at recent meeting, partnership the
about the was and new meetings attended A by of he the the have an Visiopharm tell fruition is While interesting the these headline, I of power content capabilities group story of how leader and that to partnership challenges this came high inspired user first the mass from images. imaging on to technologies. our cytometry shows software meeting, depicting
To some Imaging System meeting, own workflow. software incredible user These faster the with At increased market year's our partnerships he As in announcement automate extent, pharma our SironaDx second this by customers. his drive was software the accelerating the and group sales. and medical SironaDx. today center adoption. we further A reagents our presentations strengthened Hyperion shared on concert of from the explains pull-through a to this meeting developed offerings, witnessed result, result academic
are we decision number they and launched already base. result, pharma to and Hyperion, using imaging adding hand. our a to they applications Shifting a market to new contracts the expand with customer As new the microfluidics, made services cytometry mass of in partnerships
we applications don't our talk a business. year the have new franchise, this that Although we that often launched about lot single-cell genomics sustained have
an for quarter, unique sequencing business, launched on to single-cell tools In total providing providing advance RNA expression to agreement competing development. applications, therapeutic cellular states market we RNA our genomics our research expanded IO high-throughput CX, best-in-class comprehensive for characterize from customers we functional subtypes announced with a systems. and gene analysis deeply and extraction workflow, two to solution with immuno-oncology to unavailable This GenomOncology new data
market Finally, we saw potential. publications deepening at recently point notable some that
Let me Examples. share Two just
cancer, to Journal ago research understand characterize to functionally fatal UCSF the that publication a measure reference was would Similar infection PML, by autoimmune The subject differentiation research. that allogeneic line the AIDS, and UCFS Phase an encourage a provides with study, for to responses learn It next trial England XX,XXX Project, forward genomics will XX be that in Northrop and The In to visit that couple cell for open genome and base system a more. step the in you is website important like Immunomes as an expansion across Grumman for project mass populations. researchers immune the human conducted parameter Medicine. of used the New cytometry further and XX,XXX a the Immunomes human II in immune a system, diseases used diverse included exciting to part thousand Information Health compromise clinical an range of diseases weeks mass diseases. is project of highlight standard to immune healthy Systems I often provides T of I foundational IT. a this space, to panel including cytometry project example, clinical a system, associated published that was brain First,
to using manner populations functions wide phenotypes Specifically, service were across not simply of that and other profile mass the technologies characterize T markers technology. to researchers intracellular cell able use They and the in donor deeply a could Fluidigm immune cell recipient range a cytometry match. CyTOF cell and
of mass Vikram? leading It We and are new These informing examples how the within floating of further two offer the these out T see however, a to to free turn is repertoire our additional therapies insights power of in results taking cell analytes. review lives. demonstrating are many, toward early cell the pleased our of the to forward way for still prominent I'd steps Vikram, our CFO, technologies financial development role cytometry just days; results. a tissue, utilizing are new immunotherapies. to call save over now the
